Supplementary Figures S1-S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Le résumé fourni par la source

Supplementary Figure 1. The RAS(ON) inhibitor doublet induces deep and durable responses in KRASG12C-mutant NSCLC models and is tolerated based on animal body weight assessment. Supplementary Figure 2. The RAS(ON) inhibitor doublet demonstrates combinatorial benefit in vitro. Supplementary Figure 3. The RAS(ON) inhibitor doublet demonstrates combinatorial benefit in vivo. Supplementary Figure 4. Graphical representation of the combined PK/TE/PD model. Supplementary Figure 5. Elironrasib and daraxonrasib synergize and drive ICD and immune dependent CR in the KPAR1.3 model. Supplementary Figure 6. The RAS(ON) doublet increases depth of response in the 3LL-ΔNRAS model. Supplementary Figure 7. Immuno-sequencing (TCRB assay) of gDNA extracted from 3LL-ΔNRAS tumors collected at 24 hours post 8 days of daily oral treatment with vehicle, elironrasib at 30 mg/kg or daraxonrasib at 25 mg/kg or the RAS(ON) doublet.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.